Modulation of prosurvival signaling in fibroblasts by a protein kinase inhibitor protects against fibrotic tissue injury

Ragini Vittal, Jeffrey C. Horowitz, Bethany B. Moore, Hengmin Zhang, Fernando J. Martinez, Galen B. Toews, Theodore J. Standiford, Victor J. Thannickal

Research output: Contribution to journalArticle

92 Citations (Scopus)

Abstract

Progressive fibrotic diseases involving diverse organ systems are associated with the persistence of fibroblasts/myofibroblasts in injured tissues. Activation of focal adhesion kinase (FAK) and protein kinase B (PKB/Akt) by transforming growth factor-β1 mediate stable induction of myofibroblast differentiation and survival. In this report, we demonstrate that transforming growth factor-β1-induced activation of both PKB/Akt and FAK are dose dependency inhibited by the protein kinase inhibitor, AG1879, in cultured human lung flbroblasts. In a murine model of intratracheal bleomycin-induced lung fibrosis, regions of active fibrogenesis demonstrate elevated expression of PKB/Akt and FAK phosphorylation in vivo, effects that are attenuated in mice receiving daily intraperitoneal infections of AG1879 (bleomycin-AG1879) versus a chemically inactive analog (bleomycin-control). PKB/Akt and FAK phosphorylation are elevated in fibroblasts isolated from lungs of bleomycin-injured mice, effects that are inhibited in bleomycin-AG1879 mice. Accumulation of α-smooth muscle actin-expressing myofibroblasts is markedly reduced in lungs of bleomycin-AG1879 mice. The numbers of recruited inflammatory cells were not significantly different between these groups. Bleomycin-AG1879 mice are protected from lung flbrosis as evidenced by histopathology, trichrome staining, and biochemical analysis for collagen. Thus, targeting of prosurvival signaling pathways in fibroblasts/myofibroblasts may provide a novel and effective strategy for anti-fibrotic therapy of treatment-unresponsive fibrotic disorders.

Original languageEnglish (US)
Pages (from-to)367-375
Number of pages9
JournalAmerican Journal of Pathology
Volume166
Issue number2
StatePublished - Feb 2005
Externally publishedYes

Fingerprint

Protein Kinase Inhibitors
Bleomycin
Focal Adhesion Protein-Tyrosine Kinases
Myofibroblasts
Fibroblasts
Wounds and Injuries
Lung
Transforming Growth Factors
Phosphorylation
Proto-Oncogene Proteins c-akt
Smooth Muscle
AG 1879
Actins
Fibrosis
Collagen
Staining and Labeling
Survival
Infection

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this

Vittal, R., Horowitz, J. C., Moore, B. B., Zhang, H., Martinez, F. J., Toews, G. B., ... Thannickal, V. J. (2005). Modulation of prosurvival signaling in fibroblasts by a protein kinase inhibitor protects against fibrotic tissue injury. American Journal of Pathology, 166(2), 367-375.

Modulation of prosurvival signaling in fibroblasts by a protein kinase inhibitor protects against fibrotic tissue injury. / Vittal, Ragini; Horowitz, Jeffrey C.; Moore, Bethany B.; Zhang, Hengmin; Martinez, Fernando J.; Toews, Galen B.; Standiford, Theodore J.; Thannickal, Victor J.

In: American Journal of Pathology, Vol. 166, No. 2, 02.2005, p. 367-375.

Research output: Contribution to journalArticle

Vittal, R, Horowitz, JC, Moore, BB, Zhang, H, Martinez, FJ, Toews, GB, Standiford, TJ & Thannickal, VJ 2005, 'Modulation of prosurvival signaling in fibroblasts by a protein kinase inhibitor protects against fibrotic tissue injury', American Journal of Pathology, vol. 166, no. 2, pp. 367-375.
Vittal, Ragini ; Horowitz, Jeffrey C. ; Moore, Bethany B. ; Zhang, Hengmin ; Martinez, Fernando J. ; Toews, Galen B. ; Standiford, Theodore J. ; Thannickal, Victor J. / Modulation of prosurvival signaling in fibroblasts by a protein kinase inhibitor protects against fibrotic tissue injury. In: American Journal of Pathology. 2005 ; Vol. 166, No. 2. pp. 367-375.
@article{ea443617d9914789920a6e708493cbf6,
title = "Modulation of prosurvival signaling in fibroblasts by a protein kinase inhibitor protects against fibrotic tissue injury",
abstract = "Progressive fibrotic diseases involving diverse organ systems are associated with the persistence of fibroblasts/myofibroblasts in injured tissues. Activation of focal adhesion kinase (FAK) and protein kinase B (PKB/Akt) by transforming growth factor-β1 mediate stable induction of myofibroblast differentiation and survival. In this report, we demonstrate that transforming growth factor-β1-induced activation of both PKB/Akt and FAK are dose dependency inhibited by the protein kinase inhibitor, AG1879, in cultured human lung flbroblasts. In a murine model of intratracheal bleomycin-induced lung fibrosis, regions of active fibrogenesis demonstrate elevated expression of PKB/Akt and FAK phosphorylation in vivo, effects that are attenuated in mice receiving daily intraperitoneal infections of AG1879 (bleomycin-AG1879) versus a chemically inactive analog (bleomycin-control). PKB/Akt and FAK phosphorylation are elevated in fibroblasts isolated from lungs of bleomycin-injured mice, effects that are inhibited in bleomycin-AG1879 mice. Accumulation of α-smooth muscle actin-expressing myofibroblasts is markedly reduced in lungs of bleomycin-AG1879 mice. The numbers of recruited inflammatory cells were not significantly different between these groups. Bleomycin-AG1879 mice are protected from lung flbrosis as evidenced by histopathology, trichrome staining, and biochemical analysis for collagen. Thus, targeting of prosurvival signaling pathways in fibroblasts/myofibroblasts may provide a novel and effective strategy for anti-fibrotic therapy of treatment-unresponsive fibrotic disorders.",
author = "Ragini Vittal and Horowitz, {Jeffrey C.} and Moore, {Bethany B.} and Hengmin Zhang and Martinez, {Fernando J.} and Toews, {Galen B.} and Standiford, {Theodore J.} and Thannickal, {Victor J.}",
year = "2005",
month = "2",
language = "English (US)",
volume = "166",
pages = "367--375",
journal = "American Journal of Pathology",
issn = "0002-9440",
publisher = "Elsevier Inc.",
number = "2",

}

TY - JOUR

T1 - Modulation of prosurvival signaling in fibroblasts by a protein kinase inhibitor protects against fibrotic tissue injury

AU - Vittal, Ragini

AU - Horowitz, Jeffrey C.

AU - Moore, Bethany B.

AU - Zhang, Hengmin

AU - Martinez, Fernando J.

AU - Toews, Galen B.

AU - Standiford, Theodore J.

AU - Thannickal, Victor J.

PY - 2005/2

Y1 - 2005/2

N2 - Progressive fibrotic diseases involving diverse organ systems are associated with the persistence of fibroblasts/myofibroblasts in injured tissues. Activation of focal adhesion kinase (FAK) and protein kinase B (PKB/Akt) by transforming growth factor-β1 mediate stable induction of myofibroblast differentiation and survival. In this report, we demonstrate that transforming growth factor-β1-induced activation of both PKB/Akt and FAK are dose dependency inhibited by the protein kinase inhibitor, AG1879, in cultured human lung flbroblasts. In a murine model of intratracheal bleomycin-induced lung fibrosis, regions of active fibrogenesis demonstrate elevated expression of PKB/Akt and FAK phosphorylation in vivo, effects that are attenuated in mice receiving daily intraperitoneal infections of AG1879 (bleomycin-AG1879) versus a chemically inactive analog (bleomycin-control). PKB/Akt and FAK phosphorylation are elevated in fibroblasts isolated from lungs of bleomycin-injured mice, effects that are inhibited in bleomycin-AG1879 mice. Accumulation of α-smooth muscle actin-expressing myofibroblasts is markedly reduced in lungs of bleomycin-AG1879 mice. The numbers of recruited inflammatory cells were not significantly different between these groups. Bleomycin-AG1879 mice are protected from lung flbrosis as evidenced by histopathology, trichrome staining, and biochemical analysis for collagen. Thus, targeting of prosurvival signaling pathways in fibroblasts/myofibroblasts may provide a novel and effective strategy for anti-fibrotic therapy of treatment-unresponsive fibrotic disorders.

AB - Progressive fibrotic diseases involving diverse organ systems are associated with the persistence of fibroblasts/myofibroblasts in injured tissues. Activation of focal adhesion kinase (FAK) and protein kinase B (PKB/Akt) by transforming growth factor-β1 mediate stable induction of myofibroblast differentiation and survival. In this report, we demonstrate that transforming growth factor-β1-induced activation of both PKB/Akt and FAK are dose dependency inhibited by the protein kinase inhibitor, AG1879, in cultured human lung flbroblasts. In a murine model of intratracheal bleomycin-induced lung fibrosis, regions of active fibrogenesis demonstrate elevated expression of PKB/Akt and FAK phosphorylation in vivo, effects that are attenuated in mice receiving daily intraperitoneal infections of AG1879 (bleomycin-AG1879) versus a chemically inactive analog (bleomycin-control). PKB/Akt and FAK phosphorylation are elevated in fibroblasts isolated from lungs of bleomycin-injured mice, effects that are inhibited in bleomycin-AG1879 mice. Accumulation of α-smooth muscle actin-expressing myofibroblasts is markedly reduced in lungs of bleomycin-AG1879 mice. The numbers of recruited inflammatory cells were not significantly different between these groups. Bleomycin-AG1879 mice are protected from lung flbrosis as evidenced by histopathology, trichrome staining, and biochemical analysis for collagen. Thus, targeting of prosurvival signaling pathways in fibroblasts/myofibroblasts may provide a novel and effective strategy for anti-fibrotic therapy of treatment-unresponsive fibrotic disorders.

UR - http://www.scopus.com/inward/record.url?scp=13244249987&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=13244249987&partnerID=8YFLogxK

M3 - Article

VL - 166

SP - 367

EP - 375

JO - American Journal of Pathology

JF - American Journal of Pathology

SN - 0002-9440

IS - 2

ER -